{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:16:22Z","timestamp":1783448182494,"version":"3.55.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 remains a leading infectious cause of death and hospitalisation globally. Coinfections with SARS-CoV-2 and other respiratory pathogens may result in more severe illness, however the prevalence of coinfection in Australia is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This Australian study aimed to determine the prevalence and microbiology of respiratory and bloodstream coinfections, antimicrobial use, and outcomes in hospitalised patients with moderate to severe COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of adult patients with moderate to severe COVID-19, admitted at the Sunshine Coast University Hospital from February to July 2022. Data regarding patient characteristics, comorbidities, microbiological results, hospital length of stay, intensive care unit admission, and mortality were compared between the coinfection and no-coinfection groups. Logistic regression analysis was performed to identify factors associated with coinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Coinfection was documented in 23 (12%) of the 190 patients admitted with moderate-severe COVID-19. Bacterial infections were the most common (54% of coinfection episodes), followed by fungal (32%), and viral (14%). Antibiotics were prescribed for 74% of patients, for a median duration of 6 days (IQR 4\u20138 days). Patients with coinfection had a median length of stay of 9 days (IQR: 4\u201319.5) compared to 6 days in the no-coinfection group (IQR: 3\u20139;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). There was no mortality difference between the two groups. Patients admitted to intensive care had higher odds of coinfection compared to patients not admitted to intensive care (OR 3.39, 95% CI 1.19\u20139.66,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Severe COVID-19 and Aboriginal and Torres Strait Islander descent were also associated with coinfection. The causal nature of these relationships requires further interrogation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of respiratory and bloodstream coinfection was low in our cohort of hospitalised COVID-19 patients. Despite non-standardised microbiological testing, antibiotic use was disproportionately high. Further work is required to define risk factors and improve diagnosis of COVID-19-associated coinfection, to better inform antimicrobial stewardship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0352344","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:34:53Z","timestamp":1783445693000},"page":"e0352344","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6554-9135","authenticated-orcid":true,"given":"Laura","family":"Frederiksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha","family":"Subedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keat","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"1","key":"pone.0352344.ref001","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41598-021-83040-3","article-title":"Years of life lost to COVID-19 in 81 countries","volume":"11","author":"H Pifarr\u00e9 i Arolas","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0352344.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251170","article-title":"Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis","volume":"16","author":"JS Musuuza","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"pone.0352344.ref003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12879-025-10521-5","article-title":"Co-infection of SARS-CoV-2 and influenza A\/B among patients with COVID-19: a systematic review and meta-analysis","volume":"25","author":"M Golpour","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0352344.ref004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41479-021-00083-w","article-title":"The role of co-infections and secondary infections in patients with COVID-19","volume":"13","author":"C Feldman","year":"2021","journal-title":"Pneumonia (Nathan)"},{"issue":"2","key":"pone.0352344.ref005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/23744235.2020.1839672","article-title":"Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands","volume":"53","author":"Z Karami","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"pone.0352344.ref006","first-page":"2049936120978095","article-title":"Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster","volume":"7","author":"LS-K Cheng","year":"2020","journal-title":"Ther Adv Infect Dis"},{"issue":"10","key":"pone.0352344.ref007","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study","volume":"72","author":"VM Vaughn","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0352344.ref008","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jac\/dkaa475","article-title":"An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London","volume":"76","author":"L Wang","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"pone.0352344.ref009","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/cid\/ciaa530","article-title":"Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing","volume":"71","author":"TM Rawson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0352344.ref010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cmi.2020.07.041","article-title":"Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study","volume":"27","author":"C Garcia-Vidal","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0352344.ref011","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13054-022-04108-8","article-title":"Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set","volume":"26","author":"A Conway Morris","year":"2022","journal-title":"Crit Care"},{"issue":"10334","key":"pone.0352344.ref012","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(22)00383-X","article-title":"SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses","volume":"399","author":"MC Swets","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"pone.0352344.ref013","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/v15040865","article-title":"COVID-19 and respiratory virus co-infections: A systematic review of the literature","volume":"15","author":"HC Maltezou","year":"2023","journal-title":"Viruses"},{"issue":"8","key":"pone.0352344.ref014","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","article-title":"COVID-19-associated fungal infections","volume":"7","author":"M Hoenigl","year":"2022","journal-title":"Nat Microbiol"},{"issue":"1","key":"pone.0352344.ref015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jmii.2020.09.004","article-title":"COVID-19 associated with pulmonary aspergillosis: A literature review","volume":"54","author":"C-C Lai","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"pone.0352344.ref016","doi-asserted-by":"crossref","first-page":"106324","DOI":"10.1016\/j.ijantimicag.2021.106324","article-title":"Increased antimicrobial resistance during the COVID-19 pandemic","volume":"57","author":"C-C Lai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"18","key":"pone.0352344.ref017","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1007\/s00253-020-10814-6","article-title":"The microbial coinfection in COVID-19","volume":"104","author":"X Chen","year":"2020","journal-title":"Applied Microbiology and Biotechnology"},{"key":"pone.0352344.ref018","doi-asserted-by":"crossref","first-page":"6840605","DOI":"10.1155\/sci5\/6840605","article-title":"Diagnostic challenges in fungal coinfections associated with global COVID-19","volume":"2025","author":"AS Jafari","year":"2025","journal-title":"Scientifica (Cairo)"},{"key":"pone.0352344.ref019","unstructured":"National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. 72. 2023. https:\/\/livingevidence.org.au\/living-guidelines\/covid-19\/"},{"issue":"9","key":"pone.0352344.ref020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cmi.2018.03.030","article-title":"Contaminants in blood cultures: importance, implications, interpretation and prevention","volume":"24","author":"S Darg\u00e8re","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"pone.0352344.ref021","unstructured":"Australian Technical Advisory Group on Immunisation ATAGI. Australian Immunisation Handbook. Australian Government Department of Health and Aged Care. https:\/\/immunisationhandbook.health.gov.au 2024. Accessed 2024 October 18."},{"issue":"3","key":"pone.0352344.ref022","first-page":"1","article-title":"Circulation of influenza and other respiratory viruses during the COVID-19 pandemic in Australia and New Zealand, 2020-2021","volume":"14","author":"GK O\u2019Neill","year":"2023","journal-title":"Western Pac Surveill Response J"},{"issue":"8","key":"pone.0352344.ref023","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3201\/eid2608.201229","article-title":"Decreased influenza incidence under COVID-19 control measures, Singapore","volume":"26","author":"RJJ Soo","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"pone.0352344.ref024","doi-asserted-by":"crossref","first-page":"00113","DOI":"10.1183\/23120541.00113-2022","article-title":"Advances in diagnostic tools for respiratory tract infections: from tuberculosis to COVID-19 - changing paradigms?","volume":"8","author":"Z Stojanovic","year":"2022","journal-title":"ERJ Open Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:35:04Z","timestamp":1783445704000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0352344"}},"subtitle":[],"editor":[{"given":"Nosheen","family":"Nasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0352344","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}